Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia.

Authors :: Byrd, John C.
Furman, Richard R.
Coutre, Steven E.
Flinn, lan W.
Burger, Jan A.
Blum, Kristie A.
Grant, Barbara
Sharman, Jeff P.
Coleman, Morton
Wierda, William G.
Jones, Jeffrey A.
Zhao, Weiqiang
Heerema, Nyla A.
Johnson, Amy J.
Sukbuntherng, Juthamas
Chang, Betty Y.
Clow, Fong
Hedrick, Eric
Buggy, Joseph J.
James, Danelle F.
Source :: New England Journal of Medicine. 7/4/2013, Vol. 369 Issue 1, p32-42. 11p.
Publication Year :: 2013
Abstract: The article presents a multicenter study which explores the effectiveness of ibrutinib against relapsed chronic lymphocytic leukemia (CLL). Bone marrow biopsy was conducted in patients with relapsed CLL to demonstrate the response rate and progression of the disease. Results show a 75% progression-free survival and 83% overall survival rate at 26 months.